Clinical Trial Update: Detour2 Continued Access Study [NA]

View source ↗

Summary

The Detour2 Continued Access Study by Endologix for peripheral artery disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Artery Disease

Drugs mentioned

• Detour2

Snippet

Sponsor: Endologix | Conditions: Peripheral Artery Diseases | NA | Status: COMPLETED